Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03826628 |
Recruitment Status :
Completed
First Posted : February 1, 2019
Last Update Posted : July 28, 2022
|
Sponsor:
Dermatology Specialties Limited Partnership
Information provided by (Responsible Party):
Dermatology Specialties Limited Partnership
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | July 12, 2022 |
Actual Study Completion Date : | July 12, 2022 |